中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2273 records (took 0.035 seconds)

    S-rabeprazole compositions and methods
    52.
    发明申请
    S-rabeprazole compositions and methods 审中-公开
    S-雷贝拉唑组合物和方法

    公开(公告)号：US20020115691A1

    公开(公告)日：2002-08-22

    申请号：US10082571

    申请日：2002-02-25

    Applicant: SEPRACOR INC.

    Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/4439

    CPC classification number: A61K31/4439 ,  A61K31/00

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯（ - ）雷贝拉唑治疗人类溃疡的方法和组合物，同时显着降低与雷贝拉唑外消旋混合物相关的副作用的伴随的责任。 光学纯的（ - ）异构体也可用于治疗胃食管反流。 （ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-) -bupropion
    53.
    发明申请
    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-) -bupropion 审中-公开
    使用光学纯（ - ） - 安非他酮有助于戒烟和治疗疼痛和其他疾病的方法和组合物

    公开(公告)号：US20040225020A1

    公开(公告)日：2004-11-11

    申请号：US10848069

    申请日：2004-05-19

    Applicant: Sepracor Inc.

    Inventor： John R. McCullough ,  Paul D. Rubin

    IPC: A61K031/137

    CPC classification number: A61K31/137 ,  A61K31/135

    Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

    Abstract translation: 公开了使用安非他酮的光学纯的（ - ） - 异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

    S(-)rabeprazole compositions and methods
    54.
    发明申请
    S(-)rabeprazole compositions and methods 审中-公开
    S（ - ）雷贝拉唑组合物和方法

    公开(公告)号：US20040171647A1

    公开(公告)日：2004-09-02

    申请号：US10796354

    申请日：2004-03-08

    Applicant: Sepracor Inc.

    Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/4439

    CPC classification number: A61K31/4439 ,  A61K31/00

    Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Methods of treating and preventing depression using didesmethylsibutramine
    55.
    发明申请
    Methods of treating and preventing depression using didesmethylsibutramine 审中-公开
    使用二甲基西布曲明治疗和预防抑郁症的方法

    公开(公告)号：US20040092481A1

    公开(公告)日：2004-05-13

    申请号：US10693980

    申请日：2003-10-28

    Applicant: Sepracor, Inc.

    Inventor： Thomas P. Jerussi

    IPC: A61K031/724 ,  A61K031/137 ,  A61K031/519

    CPC classification number: A61K31/50 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/44 ,  A61K31/475 ,  A61K31/495 ,  A61K31/505 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

    Abstract translation: 公开了用于治疗和预防疾病和病症的方法，例如但不限于：进食障碍; 体重增加; 肥胖; 过敏性肠综合征; 强迫症; 血小板粘附; 呼吸暂停 情感障碍，如注意力缺陷障碍，抑郁症和焦虑症; 男性和女性性功能障碍; 不安腿综合征 骨关节炎 药物滥用，包括尼古丁和可卡因成瘾; 发作性睡病 疼痛如神经性疼痛，糖尿病性神经病和慢性疼痛; 偏头痛 脑功能障碍; 慢性疾病如经前期综合征; 和失禁。 还公开了药物组合物和剂型，其包含外消旋或光学纯的西布曲明代谢物和任选的另外的药理活性化合物。

    Methods of treating or preventing erectile dysfunction
    56.
    发明申请
    Methods of treating or preventing erectile dysfunction 失效
    治疗或预防勃起功能障碍的方法

    公开(公告)号：US20030195261A1

    公开(公告)日：2003-10-16

    申请号：US10395298

    申请日：2003-03-25

    Applicant: Sepracor Inc.

    Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

    IPC: A61K031/137

    CPC classification number: A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutrarnine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

    Abstract translation: 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布睾胺代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的另外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT <3> 拮抗剂。

    Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
    58.
    发明申请
    Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 失效
    光学活性的5H-吡咯并[3,4-b]吡嗪衍生物，其制备方法和含有它的药物组合物

    公开(公告)号：US20020193378A1

    公开(公告)日：2002-12-19

    申请号：US10200510

    申请日：2002-07-23

    Applicant: SEPRACOR INC.

    Inventor： Claude Cotrel ,  Gerard Roussel

    IPC: A61K031/498

    CPC classification number: C07D487/04

    Abstract: Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-null(4-methyl-1-piperazinyl)carbonyloxynull-7-oxo-6,7-dihydro-5H-pyrrolonull3,4-bnullpyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.

    Abstract translation: -6 - （5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b] 吡嗪，其制剂和含有它的药物组合物，其可用作镇静剂和催眠药

Patent Agency Ranking